-
Renmark Virtual Non-Deal Roadshow: NASDAQ - INM (ID 2858)
- Overview 1 Intro 0:00:00 2 Forward Looking Statements 0:00:39 3 Executive Summary & Highlights 0:00:57 4 Pharmaceutical Pipeline 0:02:00
- Alzheimer’s Disease 5 Major Medical & Societal Burden 0:02:13 6 Neuroinflammation Response 0:02:33 7 Microglia and Astrocytes 0:03:36 8 Role of CB1/CB2 Receptors i 0:04:16
- INM-901 9 Mechanism of Action 0:04:49 10 Positive Impacts on AD Pathologies 0:05:18 11 Proof of Concept in Alzheimer’s 0:06:21 12 Positive Trends Across all Parameters 0:08:13 13 Summary 0:09:50
- AMD 14 Macular Degeneration 0:10:57 15 Occurs When Macula is Damaged 0:11:35 16 INM-089: A Differentiated Approach 0:12:29 17 INM-755 Cannabinol (CBN) Cream 0:13:03 18 Pipeline Next Steps 0:15:22
- Corporate 19 Experienced Team 0:16:37 20 Financial Snapshot 0:17:25
- Summary 21 Key Value Drivers – 2026/2027 0:18:05 22 Contact Info 0:18:54
- Question Period 23 Questions 0:18:57 24 Internally Developed Assets? 0:19:02 25 Quarterly Burn & Cash Runway? 0:19:20 26 BayMedica? 0:20:09 27 Partnership Strategy? 0:21:20 28 Upcoming Catalysts? 0:22:43 29 Other Indications? 0:24:04 30 INM-901 IND Package? 0:26:07 31 INM-901 Disease Modification? 0:27:12 32 Early or Late-Stage Disease? 0:28:23 33 INM-901 Oral Formulation? 0:30:00 34 INM-901 Monotherapy? 0:30:49
- Final Remarks 35 Outro 0:31:51
0:00:00 | 0:33:04
Renmark Virtual Non-Deal Roadshow: NASDAQ - INM (ID 2858)
Subscribe
Open Interactive SlidelistSlidelist
